Cencora, Inc. (COR) - Fiscal 2025 10-K Summary
Business Context and Reporting Period
Company: Cencora, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended September 30, 2025
Business Overview: Cencora is a leading global pharmaceutical sourcing and distribution services company. It operates through two primary reportable segments: U.S. Healthcare Solutions (human and animal health distribution) and International Healthcare Solutions (wholesale and commercialization services). The company distributes brand-name, specialty, and generic pharmaceuticals to healthcare providers and manufacturers.
Key Financial Metrics (Fiscal 2025)
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Revenue | $321.33 billion | $293.96 billion | +9.3% |
| Gross Profit | $11.48 billion | $9.91 billion | +15.8% |
| Operating Income | $2.63 billion | $2.18 billion | +20.8% |
| Net Income (Attributable to Cencora) | $1.55 billion | $1.51 billion | +3.0% |
| Diluted EPS | $7.96 | $7.53 | +5.7% |
| Operating Cash Flow | $3.88 billion | $3.48 billion | +11.2% |
| Total Debt | $7.66 billion | $4.39 billion | +74.5% |
| Cash & Equivalents | $4.36 billion | $3.13 billion | +39.4% |
Margins: Gross margin was 3.57% (up from 3.37% in 2024). Operating margin was 0.82% (up from 0.74% in 2024).
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 9.7% increase in U.S. Healthcare Solutions revenue, largely due to unit volume growth and a $7.7 billion increase in sales of GLP-1 class products (diabetes/weight loss). International Healthcare Solutions revenue grew 6.1%.
- Acquisition Impact: The January 2025 acquisition of Retina Consultants of America (RCA) for approximately $5.68 billion (including contingent consideration) contributed significantly to U.S. segment growth and operating expenses.
- Impairments: Recorded a $723.9 million goodwill impairment charge related to the PharmaLex reporting unit due to weakening demand for specialized life sciences services. This was a non-cash charge.
- Debt Structure: Total debt increased significantly due to new financing ($1.8 billion in senior notes and $1.5 billion term loan) used to fund the RCA acquisition.
- Antitrust Gains: Recognized $236.4 million in gains from antitrust litigation settlements, recorded as a reduction to Cost of Goods Sold.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Strategic Review: The company is reorganizing its reporting structure effective Q1 Fiscal 2026 to include a new "Other" segment for businesses exploring strategic alternatives (e.g., MWI Animal Health, Profarma).
- Capital Allocation: The company expects to spend approximately $900 million on capital expenditures in Fiscal 2026, focusing on distribution network expansion and technology.
- Dividends: The Board increased the quarterly dividend to $0.60 per share (a 9% increase) in November 2025.
Key Risks and Contingencies:
- Opioid Litigation: A significant liability of $4.3 billion is accrued for the Distributor Settlement Agreement and other opioid-related litigation, payable over 13 years. $416 million is due within the next 12 months.
- Customer Concentration: Walgreens and Boots UK Ltd. collectively accounted for approximately 25% of revenue and 38% of accounts receivable. The recent acquisition of Walgreens Boots Alliance by Sycamore Partners introduces uncertainty regarding future contract terms.
- Regulatory Environment: Risks include changes in U.S. healthcare policy (e.g., IRA price negotiation, OBBBA), supply chain security regulations (DSCSA), and potential tariffs on pharmaceutical imports.
- Cybersecurity: The company faces evolving cyber threats, including AI-driven attacks, which could disrupt operations or compromise data.
Investor Verification Checklist
- RCA Integration: Verify the progress of integrating Retina Consultants of America and whether it is meeting the performance targets required for contingent consideration payments.
- Opioid Settlement Payments: Monitor cash flow impacts from the $416 million in opioid settlement payments due in the coming fiscal year.
- PharmaLex Performance: Assess the turnaround strategy for PharmaLex following the full goodwill impairment and the decision to explore strategic alternatives for certain components.
- GLP-1 Product Mix: Evaluate the sustainability of revenue growth driven by GLP-1 products, noting that these products often carry lower gross profit margins.
- Walgreens/Boots Relationship: Monitor any changes in contract terms or volume following the change in ownership of Walgreens Boots Alliance.